The elucidation of myocardial protection effect and the development of myocardial protective strategy by beta-blocker, landiolol, in children.

β受体阻滞剂兰地洛尔对儿童心肌保护作用的阐明及心肌保护策略的制定

• 批准号: 24890292
• 负责人: MATSUMOTO Naoki
• 金额: $ 1.91万
• 依托单位: Gunma Institute of Public Health and Environmental Sciences
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Research Activity Start-up
• 财政年份: 2012
• 资助国家: 日本
• 起止时间: 2012-08-31 至 2014-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-24890292/
• 关键词: 小児先天性心疾患; 心筋保護効果; β遮断薬; ランジオロール; βブロッカー; 先天性心疾患; 経食道心エコー; 再灌流障害; 心臓手術; サイトカイン

In children with congenital heart disease patients who were scheduled for a cardiac surgery under cardio-pulmonary bypass, myocardial damage markers, cytokines, cardiac function, prognostic factors between the two groups of landiolol administration group and non-administration group, the myocardial protective effect of beta-blocker, landiolol, were compared.In landiolol administration group, increase of cytokines and myocardial damage marker were tended to be suppressed, cardiac function was also well maintained after surgery. In addition, post-operative hospital stay and intensive care unit admission period tended to be shortened in landiolol group.Administration of landiolol in the perioperative period possibly improves the prognosis for the patients with the congenital heart disease by the myocardial protective effect.

对拟行心肺转流心脏手术的先天性心脏病患儿，比较兰地洛尔给药组与未给药组心肌损伤标志物、细胞因子、心功能、预后因素、β受体阻滞剂兰地洛尔的心肌保护作用。术后细胞因子和心肌损伤标志物的升高有被抑制的趋势，心功能也得到了较好的维持。兰地洛尔组术后住院时间和重症监护时间有缩短的趋势，围手术期应用兰地洛尔可能通过心肌保护作用改善先心病患者的预后。